Tech Company Financing Transactions
Amyl Therapeutics Funding Round
Amyl Therapeutics, based in Liège, raised $9.5 million from Merieux Developpement, Noshaq and private investors.
Transaction Overview
Company Name
Announced On
9/1/2026
Transaction Type
Venture Equity
Amount
$9,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to finalize development of its clinical candidate ready for GMP manufacturing and generate the remaining preclinical in vivo efficacy and safety data required to validate its platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
LegiaPark, Boulevard Patience et Beaujonc 3, box 12
Liège, 4000
Belgium
Liège, 4000
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Amyl Therapeutics is a preclinical-stage biotechnology company pioneering Pan-Amyloid Immunotherapy (PAI), a universal approach to treating amyloid-mediated neurodegenerative diseases. Amyloid aggregates are involved in more than 30 disorders, including high-burden neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as rare conditions like systemic amyloidosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pierre Vandepapelière
Chief Financial Officer
Christophe Mathieu
Chief Scientific Officer
Damien Toulorge
VP - R & D
Julie Goemaere
Browse more venture capital transactions:
Prev: 9/1/2026: Tripo AI venture capital transaction
Next: 9/1/2026: Xorlab venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs